通过IL-10-mRNA纳米粒子对瘤免疫的系统性重编程
Chuang Liu1,2,3, Xiangang Huang1, Kok-Siong Chen2,3
1Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nature nanotechnology
|August 11, 2025
概括
静脉输入的IN-10 (IL-10) mRNA纳米颗粒克服了早期IL-10疗法的局限性,在临床前模型中增强了抗瘤免疫力和存活率. 这种新的方法在治疗各种免疫抑制瘤方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 纳米技术 纳米技术
背景情况:
- 在早期癌症试验中,重组互白素-10 (IL-10) 显示了初步的疗效,但由于瘤内积累和有限的临床益处而面临挑战.
- 以往对IL-10的试验由于对瘤的输送不足而受到阻碍,从而限制了其治疗潜力.
研究的目的:
- 在临床前瘤模型中评估静脉注射IL-10信使RNA (mRNA) 纳米粒子 (IL-10-mRNA@NPs) 的疗效.
- 评估IL-10-mRNA@NP的潜力,以克服复合IL-10治疗的局限性,并改善抗瘤免疫反应.
主要方法:
- 在临床前瘤模型中静脉注射IL-10-mRNA@NPs,包括正型肝细胞癌.
- 评估了瘤免疫细胞透,树突细胞成熟和MHC I类表达.
- 在中晚期瘤模型中,结合IL-10-mRNA@NP与免疫检查点阻塞.
主要成果:
- 在免疫抑制性瘤中,IL-10-mRNA@NPs维持了局部IL-10的产生,促进了细胞毒性T细胞透和树突细胞激活.
- 组合疗法导致43%的小鼠完全根除瘤,并使中位生存时间增加了六倍.
- 治疗诱导了持久的抗瘤免疫记忆,提供了对瘤复发的完全保护.
结论:
- 静脉注射IL-10-mRNA@NP代表了增强抗瘤免疫力和克服复合IL-10的局限性的有希望的策略.
- 这种基于纳米粒子的方法可能为广泛的免疫抑制瘤提供可行的治疗选择.
- 组合疗法显示出显著的疗效和长期缓解的潜力通过免疫记忆.
相关概念视频
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K